Table 3.
Multivariate analyses of prognostic factors for overall survival in non-APL and intermediate-risk AML cases.
| Prognostic factors | Non-APL AML | Intermediate-risk AML | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
| Sex (Male vs. Female) | 1.136 (0.713–1.812) | 0.591 | 0.876 (0.512–1.498) | 0.629 |
| Age (≤60 vs. >60 years) | 1.384 (0.905–2.117) | 0.134 | 1.116 (0.642–1.939) | 0.698 |
| WBC (≥30×109/L vs. <30×109/L) | 1.209 (0.776–1.884) | 0.401 | 1.499 (0.882–2.548) | 0.134 |
| PLT (100×109/L vs. 100×109/L) | 1.340 (0.766–2.343) | 0.305 | 1.074 (0.528–2.184) | 0.845 |
| Karyotypic classifications (favorable vs. intermediate vs. poor) | 1.683 (1.251–2.266) | 0.001 | – | – |
| POU5F1B expression (high vs. low) | 0.453 (0.241–0.852) | 0.014 | 0.448 (0.225–0.896) | 0.023 |
| IDH1/2 mutation (mutant vs. wild-type) | 4.470 (1.860–10.740) | 0.001 | 5.732 (2.197–14.960) | 0.000 |
| IDH2 R140 mutation (mutant vs. wild-type) | 0.650 (0.118–3.585) | 0.621 | 0.636 (0.102–3.948) | 0.627 |
| U2AF1 mutation (mutant vs. wild-type) | 2.452 (1.013–5.931) | 0.047 | 2.206 (0.831–5.858) | 0.112 |
| SRSF2 mutation (mutant vs. wild-type) | 1.339 (0.540–3.321) | 0.529 | 2.032 (0.766–5.390) | 0.154 |